

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Wadih Arap Renata Pasqualini	
(Use several sheets if necessary)	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3



U.S. Patent Documents

Exam. Init.	Ref. Des	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
BL	A1	2001/0046498	11/29/01	Rouslahti <i>et al.</i>	424	178.1	1/17/01
	A2	2003/0113320	6/19/03	Ruoslahti <i>et al.</i>	424	143.1	10/03/02
	A3	4,472,509	9/18/84	Gansow and Strand	436	548	6/07/82
	A4	4,912,040	3/27/90	Kaufman and Dorner	435	69.6	2/03/87
	A5	5,021,236	6/04/91	Gries <i>et al.</i>	424	9	3/02/87
	A6	5,081,034	1/14/92	Bevilasqua <i>et al.</i>	435	252.33	11/14/88
	A7	5,098,833	03/24/92	Lasky <i>et al.</i>	435	69.1	2/23/89
	A8	5,188,964	2/23/93	McGuire <i>et al.</i>	436	64	4/12/90
	A9	5,206,347	4/27/93	Ruoslahti <i>et al.</i>	530	413	7/13/90
	A10	5,216,131	6/01/93	Lasky <i>et al.</i>	435	69.1	2/23/89
	A11	5,223,409	6/29/93	Ladner <i>et al.</i>	435	69.7	3/01/91
	A12	5,225,538	7/06/93	Capon <i>et al.</i>	530	387.3	12/16/91
	A13	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	8/17/92
	A14	5,288,846	2/22/94	Quertermous <i>et al.</i>	435	172.3	8/03/92
	A15	5,304,640	4/19/94	Asky <i>et al.</i>	536	23.5	2/13/92
	A16	5,415,874	5/16/95	Bender <i>et al.</i>	424	520	10/31/89
	A17	5,428,130	6/27/95	Capon <i>et al.</i>	530	350	12/08/92
	A18	5,453,362	9/26/95	Lamarco <i>et al.</i>	435	69.1	4/12/93
	A19	5,463,026	10/31/95	Nakamura and Sato	530	387.3	2/24/94
	A20	5,492,807	2/20/96	Santi	435	5	11/19/93
↓	A21	5,506,126	4/09/96	Seed <i>et al.</i>	435	172.3	1/18/93

25480466.1

EXAMINER: /Bao Li/ (09/03/2006) DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadth Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

U.S. Patent Documents

Exam. Init.	Ref. Des	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
BL	A22	5,536,814	7/16/96	Ruoslahti <i>et al.</i>	530	329	3/11/94
	A23	5,622,699	4/22/97	Ruoslahti <i>et al.</i>	424	93.6	9/11/95
	A24	5,670,312	9/23/97	Santi	435	5	11/17/95
	A25	5,688,692	11/18/97	Jat <i>et al.</i>	435	354	2/11/93
	A26	5,688,935	11/18/97	Stephens <i>et al.</i>	536	23.1	5/03/95
	A27	5,705,610	1/06/98	Zuckerman <i>et al.</i>	530	338	10/01/93
	A28	5,750,344	5/12/98	Doyle	435	6	10/04/95
	A29	5,840,841	11/24/98	Zuckerman <i>et al.</i>	530	338	5/08/97
	A30	5,866,759	2/02/99	Jat <i>et al.</i>	800	3	7/02/97
	A31	5,902,598	5/11/99	Chen and Ashton	424	423	8/28/97
	A32	5,955,572	9/21/99	Ruoslahti and Pasqualini	530	317	5/14/98
	A33	6,068,829	5/30/00	Ruoslahti and Pasqualini	242	9.1	6/23/97
	A34	6,174,861	1/16/01	O'Reilly and Folkman	514	12	7/07/99
	A35	6,232,440	5/15/01	Hillman <i>et al.</i>	530	350	4/20/99
	A36	6,350,855	2/26/02	Tobin	530	350	9/15/97
	A37	6,399,384	6/04/02	Jat	435	456	9/15/00
↓	A38	6,458,381	10/01/02	Sourovov and Jung	424	450	2/12/97
	A39	6,528,281	3/04/03	Tobin	435	69.1	6/14/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
BL	B1	DE 19605175	8/14/97	Germany			Abstract

25480466.1

EXAMINER: /Bao Li/ (09/03/2006) DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
BL	B2	EP 0639584	4/01/98	Europe			English
	B3	WO 02/20723	3/14/02	WIPO			English
	B4	WO 02/20822	3/14/02	WIPO			English
	B5	WO 03/022991	3/20/03	WIPO			English
	B6	WO 92/00091	7/01/91	WIPO			English
	B7	WO 92/03461	3/05/92	WIPO			English
	B8	WO 92/06191	4/16/92	WIPO			English
	B9	WO 95/14714	6/01/95	WIPO			English
	B10	WO 96/34874	11/07/96	WIPO			English
	B11	WO 96/34875	11/07/96	WIPO			English
	B12	WO 97/10507	3/20/97	WIPO			English
	B13	WO 97/19954	5/06/97	WIPO			English
	B14	WO 97/30024	9/16/99	WIPO			English
	B15	WO 97/39021	10/23/97	WIPO			English
	B16	WO 98/10795	3/19/98	WIPO			English
	B17	WO 99/46284	9/16/99	WIPO			English
	B18	WO 99/57311	11/11/99	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C1	Aiello <i>et al.</i> , "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins," <i>Proc. Natl. Acad. Sci., USA</i> , 92(23):10457-10461, 1995.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C2	Aiello <i>et al.</i> , "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders," <i>N. Eng. J. Med.</i> , 331(22):1480-1487, 1994.
	C3	Alliot <i>et al.</i> , "Brain parenchyma vessels and the angiotensin system," <i>Brain Res.</i> , 830:101-112, 1999.
	C4	Alliot <i>et al.</i> , "Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin," <i>J. Neurosci. Res.</i> , 58:367-378, 1999.
	C5	Alon <i>et al.</i> , "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity," <i>Nat. Med.</i> , 1:1024-1028, 1995.
	C6	Andrade <i>et al.</i> , "Angiotensin-II-induced angiogenesis in sponge implants in mice," <i>Int. J. Microcirc. Clin. Exp.</i> , 16(6):302-307, 1996.
	C7	Arap <i>et al.</i> , "Steps toward mapping the human vasculature by phage display," <i>Nature Med.</i> , 8(2):121-127, 2002.
	C8	Arap <i>et al.</i> , "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <i>Science</i> , 279:377-380, 1998.
	C9	Arap <i>et al.</i> , "Chemotherapy targeted to tumor vasculature," <i>Curr. Opin. Oncol.</i> , 10(6):560-565, 1998.
	C10	Arap <i>et al.</i> , "Targeting the prostate for destruction through a vascular address," <i>Proc. Natl. Acad. Sci., USA</i> , 99:1527-1531, 2002.
	C11	Arden, "The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment," <i>Br. J. Ophthalmol.</i> , 85:366-370, 2001.
	C12	Asako <i>et al.</i> , "Organic solvent tolerance and antibiotic resistance increased by overexpression of marA in <i>Escherichia coli</i> ," <i>Applied Environmental Microbiology</i> , 63(4):1428-1433, 1997.
	C13	Assmann <i>et al.</i> , "A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection," <i>J. Exp. Med.</i> , 175:623-635, 1992.
	C14	Atkins <i>et al.</i> , "Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation," <i>Bone</i> , 26(6):653-661, 2000.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
		U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C15	Baillie <i>et al.</i> , "Tumor vasculature-A potential therapeutic target," <i>British J. Cancer</i> , 72:257-267, 1995.
	C16	Baringa, "Peptide-guided cancer drugs show promise in mice," <i>Science</i> , 279:323-324, 1998.
	C17	Baumann <i>et al.</i> , "Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells," <i>J. Immunol.</i> , 157(1):284-290, 1996.
	C18	Beckman <i>et al.</i> , "Experimental manipulation of the rodent visceral yolk sac," <i>Teratology</i> , 41(4):395-404, 1990.
	C19	Behm <i>et al.</i> , "Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL gene rearrangements," <i>Blood</i> , 87:1134-1139, 1996.
	C20	Bergelson <i>et al.</i> , "Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5," <i>Science</i> , 275:1320-1322, 1997.
	C21	Bergers <i>et al.</i> , "Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors," <i>J. Clin. Invest.</i> , 111(9):1287-1295, 2003.
	C22	Bicknell, "Vascular targeting and the inhibition of angiogenesis," <i>Annals of Oncology</i> , 5(Suppl 4):S45-S50, 1994.
	C23	Bigner <i>et al.</i> , "Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin sulfate proteoglycan Mel-14F(ab1)2-a preliminary report," <i>J. Neuro-Oncol.</i> , 24:109-122, 1995.
	C24	Bogenreider <i>et al.</i> , "Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue," <i>Prostate</i> , 33:225-232, 1997.
	C25	Brooks <i>et al.</i> , "Anti integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , 96:1815-1822, 1995.
✓	C26	Brooks <i>et al.</i> , "Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels," <i>Cell</i> , 79(7):1157-1164, 1994.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
		U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C27	Brooks <i>et al.</i> , "Requirement of vascular integrin $\alpha v \beta 3$ for angiogenesis," <i>Science</i> , 264:569-571, 1994.
	C28	Bumol <i>et al.</i> , "Monoclonal antibody and antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth," <i>Proc. Natl. Acad. Sci., USA</i> , 80:529-533, 1983.
	C29	Burg <i>et al.</i> , "A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen," <i>Exp. Cell Res.</i> , 235:254-264, 1997.
	C30	Burg <i>et al.</i> , "Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules," <i>J. Biol. Chem.</i> , 271(42):26110-26116, 1996.
	C31	Burg <i>et al.</i> , "Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells," <i>J. Cell. Physiol.</i> , 177:299-312, 1998.
	C32	Burg <i>et al.</i> , "NG2 proteoglycan-binding peptides target tumor neovasculature," <i>Cancer Res.</i> , 59(12):2869-2874, 1999.
	C33	Burioni <i>et al.</i> , "Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro," <i>Proc. Natl. Acad. Sci., USA</i> , 91:355-359, 1994.
	C34	Burrows and Thorpe, "Vascular targeting-A new approach to the therapy of solid tumors," <i>Pharmac. Ther.</i> , 64:155-174, 1994.
	C35	Burton <i>et al.</i> , "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," <i>Proc. Natl. Acad. Sci., USA</i> , 88:10134-10137, 1991.
	C36	Butner, "Retinitis pigmentosa and retinal neovascularization: a case report," <i>Ann. Ophthalmol.</i> , 16:861-865, 1984.
	C37	Cai <i>et al.</i> , "Induction of glucose regulated proteins during growth of a murine tumor," <i>J. Cell Physiol.</i> , 154(2):229-237, 1993.
✓	C38	Campbell <i>et al.</i> , "Prohibitin 3' untranslated region polymorphism and breast cancer risk," <i>Cancer Epidemiol. Biomarkers Prev.</i> , 12(11 pt1):1273-1274, 2003.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
		U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C39	Campfield and Smith, "Overview: neurobiology of OB protein (leptin)," Proceedings of the Nutrition Society, 57:429-440, 1998.
	C40	Campfield <i>et al.</i> , "Strategies and potential molecular targets for obesity treatment," <i>Science</i> , 280:1383-1387, 1998.
	C41	Cao <i>et al.</i> , "Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases," <i>J. Clin. Invest.</i> , 101:1055-1063, 1998.
	C42	Cattani <i>et al.</i> , "Cloning and characterization of human recombinant antibody Fab fragments specific for types 1 and 2 herpes simplex virus," <i>Microbiologica</i> , 18:135-142, 1995.
	C43	Chaverroche <i>et al.</i> , "A rapid method for efficient gene replacement in the filamentous fungus <i>Aspergillus nidulans</i> ," <i>Nucleic Acids Research</i> , 28(22):E97, 2000.
	C44	Chen <i>et al.</i> , "Thapsigargin-induced grp78 expression is mediated by the increase of cytosolic free calcium in 9L rat brain tumor cells," <i>J. Cell. Biochem.</i> , 78:404-416, 2000.
	C45	Chinni <i>et al.</i> , "Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients," <i>Clin. Cancer Res.</i> , 3:1557-1564, 1997.
	C46	Choongkittaworn <i>et al.</i> , "Expression of prohibitin in rat seminiferous epithelium," <i>Biol. Reprod.</i> , 49(2):300-310, 1993.
	C47	Curnis <i>et al.</i> , "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)," <i>Nat Biotechnol.</i> , (11):1185-90, 2000.
	C48	D'Amato <i>et al.</i> , "Thalidomide is an inhibitor of angiogenesis," <i>Proc. Natl. Acad. Sci., USA</i> , 91:4082-4085, 1994.
	C49	Davis <i>et al.</i> , "Use of a high affinity DNA ligand in flow cytometry," <i>Nucleic Acids Research</i> , 24:702-706, 1996.
	C50	Delpino <i>et al.</i> , "Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin," <i>Mol. Membr. Biol.</i> , 15(1):21-26, 1998.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C51	Deo <i>et al.</i> , "Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood," <i>J. Immunology</i> , 160:1677-1686, 1998.
	C52	Dmitriev <i>et al.</i> , "An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism," <i>J. Virol.</i> , 72(12):9706-9713, 1998.
	C53	Douglas <i>et al.</i> , "Targeted gene delivery by tropism-modified adenoviral vectors," <i>Nature Biotech.</i> , 14:1574-1578, 1996.
	C54	Drolet <i>et al.</i> , "An enzyme-linked oligonucleotide assay," <i>Nat. Biotech.</i> , 14:1021-1025, 1996.
	C55	Duh <i>et al.</i> , "Vascular endothelial growth factor and diabetes," <i>Diabetes</i> , 48:1899-1906, 1997.
	C56	Dvorak <i>et al.</i> , "Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies," <i>Cancer Cells</i> , 3:77-85, 1991.
	C57	Egeblad and Werb, "New functions for the matrix metalloproteinases in cancer progression," <i>Nat. Rev. Cancer</i> , 2:161-174, 2002.
	C58	Ellerby <i>et al.</i> , "Anti-cancer activity of targeted pro-apoptotic peptides," <i>Nature Med.</i> , 5(9):1032-8, 1999.
	C59	Finnell, "Teratology: general considerations and principles," <i>J. Allergy Clin. Immunol.</i> , 103(2 Pt 2):S337-42, 1999.
	C60	Folkman, "Addressing tumor blood vessels," <i>Nature Biotechnology</i> , 15:510, 1997.
	C61	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Biotechnol.</i> , 1:27-31, 1995.
	C62	Fujimura <i>et al.</i> , "Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression," <i>Oncology</i> , 58:342-352, 2000.
✓	C63	Furuya <i>et al.</i> , "The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin," <i>Cancer Res.</i> , 54(23):6167-6175, 1994.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C64	Fusaro <i>et al.</i> , "Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling," <i>J. Biol. Chem.</i> , 278(48):47853-47861, 2003.
	C65	Geng <i>et al.</i> , "Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinomas," <i>Anticancer Res.</i> , 18:1-7, 1998.
	C66	Giordano <i>et al.</i> , "Biopanning and rapid analysis of selective interactive ligands," <i>Nat. Med.</i> , 7(11):1249-1253, 2001.
	C67	Girod <i>et al.</i> , "Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2," <i>Nature Med.</i> , 5:1052-1056, 1999.
	C68	Goetz <i>et al.</i> , "Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flow," <i>Int. J. Cancer</i> , 65:192-199, 1996.
	C69	Gold <i>et al.</i> , "Diversity of oligonucleotide functions," <i>Annu. Rev. Biochem.</i> , 64:763-797, 1995.
	C70	Goldman <i>et al.</i> , "Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor," <i>Cancer Res.</i> , 57(8):1447-51, 1997.
	C71	Goodson <i>et al.</i> , "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," <i>Proc. Natl. Acad. Sci., USA</i> , 91:7129-7133, 1994.
	C72	Grako and Stallcup, "Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor," <i>Exp. Cell Res.</i> , 221:231-240, 1995.
	C73	Grasso <i>et al.</i> , "In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140," <i>Endocrinology</i> , 138(4):1413-1418, 1997.
	C74	Grifman <i>et al.</i> , "Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids," <i>Mol. Ther.</i> , 3(6):964-75, 2001.
	C75	Griscelli <i>et al.</i> , "Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6367-6372, 1998.
✓	C76	Hadigan <i>et al.</i> , "Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial," <i>J. Amer. Med. Assn.</i> , 284:472-477, 2000.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C77	Hammes <i>et al.</i> , "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Med.</i> , 2:529-533, 1996.
	C78	Hanahan, "Signaling vascular morphogenesis and maintenance," <i>Science</i> , 277:48-50, 1997.
	C79	Harper and Reisfeld, "Cell-associated proteoglycans in human malignant melanoma," <i>Biology of Proteoglycans</i> , Acad. Press, 345-366, 1987.
	C80	Harper and Reisfeld, "Inhibition of anchorage independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan," <i>J. Natl. Cancer Inst.</i> , 71:259-263, 1983.
	C81	Hart <i>et al.</i> , "Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide," <i>J. Biol. Chem.</i> , 269:12468-12474, 1994.
	C82	Hashizume <i>et al.</i> , "Openings between defective endothelial cells explain tumor vessel leakiness," <i>Am. J. Pathol.</i> , 156(4):1363-1380, 2000.
	C83	Hayakawa <i>et al.</i> , "Clinical features of autosomal dominant retinitis pigmentosa with rhodopsin gene codon 17 mutation and retinal neovascularization in a Japanese patient," <i>Am. J. Ophthalmol.</i> , 115:168-173, 1993.
	C84	Hicke <i>et al.</i> , "DNA aptamers block L-selectin function in vivo," <i>J. Clin. Invest.</i> , 98:2688-2692, 1996.
	C85	Hong <i>et al.</i> , "Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells," <i>EMBO J.</i> , 16:2294-2306, 1997.
	C86	Huang <i>et al.</i> , "Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature," <i>Science</i> , 275:547-550, 1997.
	C87	Iida <i>et al.</i> , "Spreading and focal contact formation of human melanoma cells in response to the stimulation of both NG2 $\alpha\beta 1$ integrin," <i>Cancer Res.</i> , 55:2177-2185, 1995.
	C88	Ikonen <i>et al.</i> , "Prohibitin, an antiproliferative protein, is localized to mitochondria," <i>FEBS Letters</i> , 358(3):273-277, 1995.
✓	C89	Ino <i>et al.</i> , "Expression of aminopeptidase A in human gestational choriocarcinoma cell lines and tissues," <i>Placenta</i> , 21:63-72, 2000.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C90	Jackson, In: <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , Hardman (eds.), McGraw-Hill Medical Publishing Division, 809-841, 2001.
	C91	Jain <i>et al.</i> , "Metabolic complications associated with antiretroviral therapy," <i>Antiviral Res.</i> , 51:151-177, 2001.
	C92	Joliot <i>et al.</i> , "alpha-2,8-Polysialic acid is the neuronal surface receptor of antenna pedia homeobox peptide," <i>New Biol.</i> , 3:1121-1131, 1991.
	C93	Joliot <i>et al.</i> , "Antenna pedia homeobox peptide regulates neural morphogenesis," <i>Proc. Natl. Acad. Sci., USA</i> , 88:1864-1868, 1991.
	C94	Juillerat-Jeanneret <i>et al.</i> , "Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta," <i>Lab. Invest.</i> , 80(6):973-980, 2000.
	C95	Juillerat-Jeanneret <i>et al.</i> , "Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature," <i>Cell Tissue Res.</i> , 311:53-59, 2003.
	C96	Jupe <i>et al.</i> , "The 3' untranslated region of prohibitin and cellular immortalization," <i>Exp. Cell Res.</i> , 224(1):128-135, 1996.
	C97	Kahler <i>et al.</i> , "Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rats," <i>Am J Physiol</i> , 275(1 Pt 2):R180-R185, 1998.
	C98	Kerbel, "Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C99	Kiang <i>et al.</i> , "17 beta-estradiol-induced increases in glucose-related protein 78kD and 94kD protect human breast cancer T47-D cells from thermal injury," <i>Chin. J. Physiol.</i> , 40(4):213-219, 1997.
	C100	Kifor and Dzau, "Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins," <i>Circ. Res.</i> , 60:422-428, 1987.
	C101	Kiovunen <i>et al.</i> , "Identification of receptor ligands with phage display peptide libraries," <i>J. Nuclear Medicine</i> , 40(5):883-888, 1999.
✓	C102	Koivunen <i>et al.</i> , "Integrin-binding peptides derived from phage display libraries," <i>Methods Mol. Biol.</i> , 129:3-17, 1999.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
		U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C103	Koivunen <i>et al.</i> , "Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins," <i>Biotechnology</i> , 13(3):265-270, 1995.
	C104	Koivunen <i>et al.</i> , "Selection of peptides binding to the alpha5 beta1 integrin from phage display library," <i>J. Biol. Chem.</i> , 268:20205-20210, 1993.
	C105	Koivunen <i>et al.</i> , "Tumor targeting with a selective gelatinase inhibitor," <i>Nat. Biotechnol.</i> , 17:768-774, 1999.
	C106	Kolonin <i>et al.</i> , "Molecular addresses in blood vessels as targets for therapy," <i>Curr. Opin. Chem. Biol.</i> , 5:308-313, 2001.
	C107	Kolonin <i>et al.</i> , "Teratogenicity induced by targeting a placental immunoglobulin transporter," <i>Proc. Natl. Acad. Sci., USA</i> , 99(20):13055-13060, 2002.
	C108	Lahdenranta <i>et al.</i> , "An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration," <i>Proc. Natl. Acad. Sci., USA</i> , 98(18):10368-10373, 2001.
	C109	Lamers and Bacher, "Prohibitin and prohibitone, ubiquitous and abundant proteins that are reluctant to reveal their real identity," <i>Int. Arch. Allergy Immunol.</i> , 113(1-3):146-149, 1997.
	C110	Lappi, "Tumor targeting through fibroblast growth factor receptors," <i>Cancer Biology</i> , 6:279-288, 1995.
	C111	Larocca <i>et al.</i> , "Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage," <i>FEBS J.</i> , 13:727-734, 1999.
	C112	Le Noble <i>et al.</i> , "The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network," <i>J. Vasc. Res.</i> , 33(6):480-488, 1996.
	C113	Le Roux <i>et al.</i> , "Neurotrophic activity of the Antenna pedia homeodomain depends on its specific DNA-binding properties," <i>Proc. Natl. Acad. Sci., USA</i> , 90:9120-9124, 1993.
	C114	Leff, "NeXstar previews 'PASS' for downstream synthesis of therapeutic oligos," <i>Bioworld Today</i> , 8:2&4, 1997.
✓	C115	Leger <i>et al.</i> , "The chondroitin sulfate proteoglycan NG2 is a tumor specific antigen on the chemically induced rat chondrosarcoma HSN," <i>Int. J. Cancer</i> , 58:700-705, 1994.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C116	Li <i>et al.</i> , "Widespread tissue distribution of aminopeptidase A, an evolutionarily conserved ectoenzyme recognized by the BP-1 antibody," <i>Tissue Antigens</i> , 42:488-496, 1993.
	C117	Lin <i>et al.</i> , "T and B cell development in BP-1/6C3/aminopeptidase A-deficient mice," <i>J. Immunol.</i> , 160(10):4681-4687, 1998.
	C118	Look <i>et al.</i> , "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," <i>J. Clin. Invest.</i> , 83:1299-1307, 1999.
	C119	Makinen <i>et al.</i> , "Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1," 274(30):21217-22, 1999.
	C120	Mandecki <i>et al.</i> , "A mathematical model for biopanning (affinity selection) using peptide libraries on filamentous phage," <i>J. Theor. Biol.</i> , 176:523-530, 1995.
	C121	Manjeshwar <i>et al.</i> , "Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer," <i>Cancer Res.</i> , 63(17):5251-5256, 2003.
	C122	Maranghi <i>et al.</i> , "Evaluation of the placenta: suggestions for a greater role in developmental toxicology," <i>Adv. Exp. Med. Biol.</i> , 444:129-136, 1998.
	C123	Martin <i>et al.</i> , "Retrovirus targeting by tropism restriction to melanoma cells," <i>J. Virol.</i> , 73:6923-6929, 1999.
	C124	Martiny-Baron and Marmé, VEGF-mediated tumor angiogenesis: a new target for cancer therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C125	McCarty <i>et al.</i> , "Quantitative and qualitative in vivo angiogenesis assay," <i>Int. J. Oncol.</i> , 21(1):5-10, 2002.
	C126	McClung <i>et al.</i> , "Prohibitin: potential role in senescence, development, and tumor suppression," <i>Exp. Gerontol.</i> , 30(2):99-124, 1995.
	C127	McConnell <i>et al.</i> , "Biopanning phage display libraries using magnetic beads vs. polystyrene plates," <i>BioTechniques</i> , 26(2):208-209, 1999.
✓	C128	Mentzel <i>et al.</i> , "Induction of albuminuria in mice: synergistic effect of two monoclonal antibodies directed to different domains of aminopeptidase A," <i>Kidney Int.</i> , 55(4):1335-1347, 1999.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C129	Miller <i>et al.</i> , "Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer," <i>Cancer Res.</i> , 58:5738, 5748, 1998.
	C130	Miner <i>et al.</i> , "Clonal drift of cell surface, melanogenic and experimental metastatic properties of in vivo-selected, brain meninges-colonizing murine B16 melanoma," <i>Cancer Research</i> , 42:4631-4638, 1982.
	C131	Misra <i>et al.</i> , "The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction," <i>J Biol Chem.</i> , 277(44):42082-7, 2002.
	C132	Monton <i>et al.</i> , "Effects of angiotensin II on endothelial cell growth: role of AT-1 and AT-2 receptors," <i>J. Am. Soc. Nephrol.</i> , 9(6):969-974, 1998.
	C133	Morikawa <i>et al.</i> , "Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors," <i>Am. J. Pathol.</i> , 160(3):985-1000, 2002.
	C134	Murphy <i>et al.</i> , "Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation," <i>J. Cell Physiol.</i> , 157(2):351-358, 1993.
	C135	Mustonen and Alitalo, "Endothelial receptor tyrosine kinases involved in angiogenesis," <i>J. Cell Biol.</i> , 129:895-898, 1995.
	C136	Nadal <i>et al.</i> , "Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF- β and BDGF-BB," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:739-748, 2002.
	C137	Nagy <i>et al.</i> , "Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent," <i>Proc. Natl. Acad. Sci., USA</i> , 93:7269-7273, 1996.
	C138	Nagy <i>et al.</i> , "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," <i>Proc. Natl. Acad. Sci., USA</i> , 95:1794-1799, 1998.
↓	C139	Nanus <i>et al.</i> , "Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A," <i>Proc. Natl. Acad. Sci., USA</i> , 90:7069-7073, 1993.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED:

09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C140	Nelson, "Parenting of therapeutics for obesity and nutritional disease," Exp Opin Ther Patents, 9(9):1185-1196, 1999.
	C141	Nishiyama and Stallcup, "Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface," <i>Mol. Biol. Cell</i> , 4:1097-1108, 1993.
	C142	Nishiyama <i>et al.</i> , "Interaction between NG2 proteoglycan and PDGF α receptor is required for optimal response to PDGF," <i>J. Neurosci. Res.</i> , 43:315-330, 1996.
	C143	Nishiyama <i>et al.</i> , "The primary structure of NG2, a novel membrane-spanning proteoglycan," <i>J. Cell. Biol.</i> , 114:359-371, 1991.
	C144	Nuell <i>et al.</i> , "Prohibitin, an evolutionary conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells," <i>Mol. Cell Biol.</i> , 11(3):1372-1381, 1991.
	C145	Okamoto <i>et al.</i> , "Transgenic mice with increased expression of vascular endothelial growth factor in the retina," <i>Am. J. Pathol.</i> , 151(1):281-291, 1997.
	C146	Oloffson <i>et al.</i> , "Phage viability in organic media: insights into phage stability," <i>J Mol Recognit</i> , 11(1-6):91-93, abstract, 1998.
	C147	Olofsson <i>et al.</i> , "Current biology of VEGF-B and VEGF-C," <i>Curr. Op. Biotechnol.</i> , 10:528-535, 1999.
	C148	Owens <i>et al.</i> , "Cloning the antibody response in humans with chronic inflammatory disease: immunopanning of subacute sclerosing panencephalitis (SSPE) brain sections with antibody phage libraries prepared from SSPE brain enriches for antibody recognizing measles virus antigens in situ," <i>J. Virol.</i> , 74(3):1533-1537, 2000.
	C149	Pasqualini and Ruoslahti, "Organ targeting in vivo using phage display peptide libraries," <i>Nature</i> , 380:364-366, 1996.
	C150	Pasqualini <i>et al.</i> , "A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins," <i>J. Cell Biol.</i> , 130:1189-1196, 1995.
	C151	Pasqualini <i>et al.</i> , "Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis," <i>Cancer Res.</i> , 60(3):722-727, 2000.
	C152	Pasqualini <i>et al.</i> , " α_v integrins as receptors for tumor targeting by circulating ligands," <i>Nature Biotechnology</i> , 15:542-546, 1997.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C153	Pasqualini <i>et al.</i> , In: <i>Phage Display: A Laboratory Manual</i> , eds. Barbas <i>et al.</i> , Cold Spring Harbor Laboratory Press, New York, NY, 22.1-24, 2000.
	C154	Pasqualini, "Vascular targeting with phage peptide libraries," <i>J. Nucl. Med.</i> , 43(2):159-162, 1999.
	C155	Pauli <i>et al.</i> , "Organ-preference of metastasis," <i>Cancer and Metastasis Reviews</i> , 9:175-189, 1990.
	C156	Pereboeva <i>et al.</i> , "Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen," <i>J. Med. Virol.</i> , 60:144-151, 2000.
	C157	Pereboeva <i>et al.</i> , "Identification of antigenic sites on three hepatitis C virus proteins using phage-displayed peptide libraries," <i>J. Med. Virol.</i> , 56:105-111, 1998.
	C158	Pierce <i>et al.</i> , "Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity," <i>Arch. Ophthalmol.</i> , 114:1219-1228, 1996.
	C159	Pierce <i>et al.</i> , "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci., USA</i> , 92(3):905-909, 1995.
	C160	Pluschke <i>et al.</i> , "Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan," <i>Proc. Natl. Acad. Sci., USA</i> , 93:9710-9715, 1996.
	C161	Prezzi <i>et al.</i> , "Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients," <i>J. Immunol.</i> , 156:4504-4513, 1996.
	C162	Pruett, "Retinitis pigmentosa: clinical observations and correlations," <i>Trans. Am. Ophthalmol. Soc.</i> , 81:693-735, 1983.
	C163	Rajotte and Ruoslahti, "Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display," <i>J. Biol. Chem.</i> , 274:11593-11598, 1999.
	C164	Rajotte <i>et al.</i> , "Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display," <i>J. Biol. Chem.</i> , 274(17):11593-11598, 1999.
↓	C165	Rajotte <i>et al.</i> , "Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display," <i>J. Clin. Invest.</i> , 102(2):430-437, 1998.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C166	Rak <i>et al.</i> , "Consequences of angiogenesis for tumor progression, metastasis and cancer therapy," <i>Anti-Cancer Drugs</i> , 6:3-18, 1995.
	C167	Raulin <i>et al.</i> , "Human immunodeficiency virus and host cell lipid. Interesting pathways in research for a new HIV therapy," <i>Prog. Lipid Res.</i> , 41:27-65, 2002.
	C168	Real <i>et al.</i> , "Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity, analysis, and comparison of antigen expression in cultured cells and tissues," <i>Cancer Res.</i> , 45:4401-4411, 1985.
	C169	Riordan, "Patents," <i>The New York Times</i> , Monday, September 15, 1997.
	C170	Roof and Makino, "Structure and function of retinal photoreceptors," <i>Principles and Practice of Ophthalmology</i> , W.B. Saunders Company, Philadelphia, 2000.
	C171	Roux <i>et al.</i> , "Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone," <i>J. Cell Physiol.</i> , 168(3):489-498, 1996.
	C172	Rugh, <i>The Mouse: Its Reproduction and Development</i> , Oxford Science Publications, Oxford, 1990.
	C173	Sang, "Complex role of matrix metalloproteinase in angiogenesis," <i>Cell Res.</i> , 8(3):171-177, 1998.
	C174	Schlingemann <i>et al.</i> , "Aminopeptidase a is a constituent of activated pericytes in angiogenesis," <i>J. Pathol.</i> , 179(4):436-442, 1996.
	C175	Schlingemann <i>et al.</i> , "Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissues," <i>Amer. J. Path.</i> , 138:1335-1347, 1991.
	C176	Schlingemann <i>et al.</i> , "Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds," <i>Amer. J. Path.</i> , 136:1393-1405, 1990.
✓	C177	Schrappe <i>et al.</i> , "Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells," <i>Cancer Res.</i> , 51:4986-4993, 1991.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C178	Scott and Smith, "Searching for peptide ligands with an epitope library," <i>Science</i> , 249:386-390, 1990.
	C179	Smith and Scott, "Libraries of peptides and proteins displayed in filamentous phage," <i>Meth. Enzymol.</i> , 21:228-257, 1993.
	C180	Smith <i>et al.</i> , "Oxygen-induced retinopathy in the mouse," <i>Invest. Ophthalmol.</i> , 35(1):101-111, 1994.
	C181	Smith, "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface," <i>Science</i> , 228:1315-1317, 1985.
	C182	Spitler <i>et al.</i> , "Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin immunotoxin," <i>Cancer Res.</i> , 47:1717-1723, 1987.
	C183	Spurdle <i>et al.</i> , "The prohibitin 3'untranslated region polymorphism is not associated with risk of ovarian cancer," <i>Gynecol. Oncol.</i> , 90(1):145-149, 2003.
	C184	St. Croix <i>et al.</i> , "Genes expressed in human tumor endothelium," <i>Science</i> , 289(5482):1197-1202, 2000.
	C185	Stone <i>et al.</i> , "Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia," <i>J. Neurosci.</i> , 15(7):4738-4747, 1995.
	C186	Tanaka <i>et al.</i> , "Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA," <i>Cancer Res.</i> , 58(15):3362-9, 1998.
	C187	Tillet <i>et al.</i> , "The membrane-spanning proteoglycan NG2 binds to collagen V and VI through central non-helical portion of the ectodomain," <i>J. Biol. Chem.</i> , 272:10769-10776, 1997.
	C188	Trepel <i>et al.</i> , "Molecular adaptors for vascular-targeted adenoviral gene delivery," <i>Hum Gene Ther.</i> , 11(14):1971-81, 2000.
	C189	Triantafilou <i>et al.</i> , "Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface," <i>Hum. Immunol.</i> , 62(8):764-770, 2001.
↓	C190	Tsimanis <i>et al.</i> , "Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia," <i>Leuk. Lymphoma</i> , 42(1-2):195-205, 2001.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C191	Uliss <i>et al.</i> , "Retinitis pigmentosa and retinal neovascularization," <i>Ophthalmology</i> , 93:1599-1603, 1986.
	C192	Verma and Somia, "Gene therapy-promises, problems, and prospects," <i>Nature</i> , 389:239-242, 1997.
	C193	Volpert <i>et al.</i> , "Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats," <i>J. Clin. Invest.</i> , 98(3):671-679, 1996.
	C194	Walsh <i>et al.</i> , "Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma," <i>Br. J. Pharmacol.</i> , 120(7):1302-1311, 1997.
	C195	Wang <i>et al.</i> , "Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function," <i>Oncogene</i> , 18(23):3501-3510, 1999.
	C196	Watkins <i>et al.</i> , "The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery," <i>Gene Ther.</i> , 4:1004-1012, 1997.
	C197	Watson <i>et al.</i> , "Variability among human umbilical vein endothelial cultures," <i>Science</i> , 268:447-448, 1995.
	C198	Weitzman <i>et al.</i> , "Adenovirus vectors in cancer gene therapy," In: <i>Gene Therapy Technology and Vector Systems</i> , 2:17-25, 1997.
	C199	Whaley <i>et al.</i> , "Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly," <i>Nature</i> , 405:665-668, 2000.
	C200	Wickham <i>et al.</i> , "Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies," <i>J. Virol.</i> , 70:6831-6838, 1996.
	C201	Wickham <i>et al.</i> , "Targeted adenovirus-mediated gene delivery to T cells via CD3," <i>J. Virol.</i> , 71(10):7663-7669, 1997.
	C202	Wickham <i>et al.</i> , "Targeting adenovirus," <i>Gene Ther.</i> , 7:110-114, 2000.
↓	C203	Wickham <i>et al.</i> , "Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation," <i>Cancer Immunol. Immunother.</i> , 45:149-151, 1997.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BL	C204	Wu <i>et al.</i> , "Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-dependent metalloproteinase family," <i>Proc. Natl. Acad. Sci., USA</i> , 87(3):993-997, 1990.
	C205	Wu, "In vivo veritas: live phage display panning," <i>Nature Biotechnology</i> , 14:429-431, 1996.
	C206	Yang and Reisfeld, "Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice," <i>Proc. Natl. Acad. Sci., USA</i> , 85:1189-1193, 1988.
	C207	Yanovski <i>et al.</i> , "Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy," <i>J. Clin. Endocrin. Metab.</i> , 84(6):1925-1931, 1999.
	C208	Yoshiji <i>et al.</i> , "The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor," <i>Clin. Cancer Res.</i> , 7(4):1073-1078, 2001.
	C209	Zempo <i>et al.</i> , "Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 16:28-33, 1996.
	C210	Zhang <i>et al.</i> , "Crystal structure of the obese protein leptin-E100," <i>Nature</i> , 387:206-209, 1997.
	C211	Zhang <i>et al.</i> , "Development and application of adenoviral vectors for gene therapy of cancer," <i>Cancer Gene Therapy</i> , 6:113-138, 1999.
	C212	Zhang <i>et al.</i> , "Inhibition of adipocyte differentiation by HIV protease inhibitors," <i>J. Clin. Endocrin. Metab.</i> , 84:4274-4277, 1999.
↓	C213	Zhang <i>et al.</i> , "Positional cloning of the mouse obese gene and its human homologue," <i>Nature</i> , 372:425-432, 1994.
	C214	Zhu <i>et al.</i> , "Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule," <i>Proc. Natl. Acad. Sci., USA</i> , 88:9568-9572, 1991.

25480466.1

EXAMINER: /Bao Li/ (09/03/2006)

DATE CONSIDERED: 09/03/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)